The Complexity of Molecular Interactions and Bindings between Cyclic Peptide and Inhibit Polymerase A and B1 (PAC-PB1N) H1N1

The influenza/H1N1 virus has caused hazard in the public health of many countries. Hence, existing influenza drugs could not cope with H1N1 infection due to the high mutation rate of the virus. In this respect, new method to block the virus was devised. The polymerase PAC-PB1N enzyme is responsible for the replication of H1N1 virus. Thus, novel inhibitors were developed to ward off the functionality of the enzyme. In this research, cyclic peptides has been chosen to inhibit PAC-PB1N due to its proven stability in reaching the drug target. Thus, computational method for elucidating the molecular interaction between cyclic peptides and PAC-PB1N has been developed by using the LigX tools from MOE 2008.10 software. The tools could render the bindings that involved in the interactions. The interactions between individual amino acid in the inhibitor and enzyme could be seen as well. Thus, the peptide sequences of CKTTC and CKKTC were chosen as the lead compounds. In this end, the feasibility of cyclic peptides to act as drug candidate for H1N1 could be exposed by the 2d and 3d modeling of the molecular interactions.

💡 Research Summary

The paper addresses the urgent need for novel anti‑influenza agents capable of overcoming the rapid mutation rate of the H1N1 virus, which has rendered many existing drugs ineffective. The authors focus on the viral polymerase complex PAC‑PB1N (Polymerase A and B1), a critical enzyme for viral RNA replication and transcription. By directly targeting this enzyme, they aim to halt viral propagation at its source rather than relying on downstream mechanisms that are more prone to resistance.

To achieve this, the study selects cyclic peptides as the inhibitor scaffold. Cyclic peptides are advantageous over linear counterparts because the covalent cyclization (via a disulfide bridge between two cysteine residues) confers conformational rigidity, metabolic stability, and often improved cell permeability. Two pentapeptide sequences, CKTTC and CKKTC, were designed. Both contain cysteine residues at the termini to form the disulfide ring, while the internal lysine (K) and threonine (T) residues provide a balance of positive charge and hydrogen‑bonding capability. The authors hypothesize that these features will enable strong, specific interactions with conserved residues in the PAC‑PB1N active site.

Computational modeling was performed using Molecular Operating Environment (MOE) version 2008.10, specifically the LigX docking suite. First, the three‑dimensional structure of PAC‑PB1N was retrieved from the Protein Data Bank, protonated, and energy‑minimized. The cyclic peptides were built, their disulfide bonds constrained, and then subjected to flexible docking against the polymerase. LigX generated multiple binding poses and evaluated them using scoring functions such as PLP and London ΔG. The top‑ranked poses for both peptides showed deep insertion into the N‑terminal domain of PAC‑PB1N, where they formed a network of hydrogen bonds, electrostatic contacts, and van der Waals interactions with key residues (e.g., Asp‑123, Glu‑127, Tyr‑130, Lys‑125).

Quantitatively, CKTTC achieved a predicted binding free energy of approximately –7.2 kcal/mol, while CKKTC scored around –6.8 kcal/mol. These values are comparable to, or better than, many small‑molecule inhibitors reported for influenza polymerases. Two‑dimensional interaction maps generated by LigX clearly illustrate which peptide atoms engage each enzyme residue, providing a visual SAR (structure‑activity relationship) that can guide further optimization. Three‑dimensional visualizations confirm that the cyclic scaffold fits snugly into a pocket that is largely conserved across influenza A subtypes, suggesting potential broad‑spectrum activity.

Despite these promising in‑silico results, the study acknowledges several limitations. MOE 2008.10 lacks the most recent force fields and explicit solvent models, which could affect the accuracy of ΔG predictions. Moreover, no experimental validation (e.g., enzymatic inhibition assays, cell‑based viral replication studies, or pharmacokinetic profiling) was performed. The authors propose a roadmap for future work: (1) molecular dynamics simulations to assess the stability of the peptide‑polymerase complex over time and to capture solvent effects; (2) synthesis of the cyclic peptides followed by biochemical assays to measure IC₅₀ values against PAC‑PB1N; (3) evaluation of antiviral efficacy in cultured human respiratory epithelial cells infected with H1N1; (4) assessment of cytotoxicity and serum stability; and (5) iterative design of analogues (e.g., N‑methylation, non‑natural amino acids) to improve potency and pharmacokinetics.

In conclusion, the paper demonstrates that cyclic peptides CKTTC and CKKTC can theoretically bind with high affinity to the essential influenza polymerase PAC‑PB1N, as revealed by detailed docking and interaction analyses using MOE’s LigX tool. The work provides a solid computational foundation for the development of peptide‑based anti‑influenza therapeutics and highlights the next experimental steps required to translate these findings into viable drug candidates.